>
Switch to:

Biomarin Pharmaceutical Earnings per Share (Diluted)

: $0.08 (TTM As of Sep. 2021)
View and export this data going back to 1999. Start your Free Trial

Biomarin Pharmaceutical's Earnings per Share (Diluted) for the three months ended in Sep. 2021 was $-0.20. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $0.08.

Biomarin Pharmaceutical's EPS (Basic) for the three months ended in Sep. 2021 was $-0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2021 was $0.09.

Biomarin Pharmaceutical's EPS without NRI for the three months ended in Sep. 2021 was $-0.20. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2021 was $0.08.

During the past 12 months, Biomarin Pharmaceutical's average EPS without NRIGrowth Rate was -98.20% per year.

During the past 13 years, Biomarin Pharmaceutical's highest 3-Year average EPS without NRI Growth Rate was 67.60% per year. The lowest was -100.00% per year. And the median was -5.75% per year.


Biomarin Pharmaceutical Earnings per Share (Diluted) Historical Data

The historical data trend for Biomarin Pharmaceutical's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Earnings per Share (Diluted)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.81 -0.67 -0.44 -0.13 4.53

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Earnings per Share (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 0.12 0.09 0.07 -0.20

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Earnings per Share (Diluted), along with its competitors' market caps and Earnings per Share (Diluted) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biomarin Pharmaceutical Earnings per Share (Diluted) Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Earnings per Share (Diluted) distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Earnings per Share (Diluted) falls into.



Biomarin Pharmaceutical Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Biomarin Pharmaceutical's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2020 is calculated as

Diluted Earnings Per Share (A: Dec. 2020 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(859.1-0)/191.678
=4.48

Biomarin Pharmaceutical's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2021 is calculated as

Diluted Earnings Per Share (Q: Sep. 2021 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-36.494-0)/183.214
=-0.20

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Biomarin Pharmaceutical  (NAS:BMRN) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biomarin Pharmaceutical Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)